SCHEMBL22014462

SCHEMBL22014462

C[C@H](O)CN1CCN(Cc2ccc(C(=O)NC(CO)C(=O)O)cc2)CCN(C[C@H](C)O)CC1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 5/20 0.51
HDAC4 P56524 3/20 0.51
KCNH2 Q12809 2/20 0.51
CA2 P00918 6/20 0.50
HDAC6 Q9UBN7 3/20 0.50
CA1 P00915 3/20 0.50
HDAC8 Q9BY41 1/20 0.47
POLB P06746 1/20 0.45
CTSL P07711 1/20 0.44
CTSB P07858 1/20 0.44
CTSS P25774 1/20 0.44
CTSK P43235 1/20 0.44
CA12 O43570 1/20 0.44
CA9 Q16790 1/20 0.44
ITGB3 P05106 1/20 0.43
ITGA2B P08514 1/20 0.43
MCHR1 Q99705 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22014470 0.90 HDAC1 (0.50) HDAC1HDAC4KCNH2CA2HDAC6
SCHEMBL22014468 0.88 HDAC4 (0.57) HDAC1HDAC4KCNH2CA2CA1
SCHEMBL10903263 0.80 HDAC1 (0.52) HDAC1HDAC4KCNH2HDAC6HDAC8
SCHEMBL22014467 0.80 HDAC1 (0.54) HDAC1HDAC4KCNH2HDAC6HDAC8
SCHEMBL10900938 0.76 CHKA (0.60) HDAC1HDAC4KCNH2HDAC6POLB
SCHEMBL22014464 0.76 HDAC6 (0.52) HDAC1HDAC4KCNH2HDAC6HDAC8
SCHEMBL24462539 0.74 ITGB3 (0.50) CA2CA1CA9ITGB3ITGA2B
SCHEMBL12983773 0.74 CA2 (0.61) CA2CA1CA12CA9
SCHEMBL12983772 0.74 CA2 (0.61) CA2CA1CA12CA9
SCHEMBL24672913 0.74 HDAC1 (0.46) HDAC1HDAC4KCNH2HDAC6HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022204065-A1 IRON(III) MACROCYCLIC COMPLEXES WITH MIXED HYROXYL PENDANTS AS MRI CONTRAST AGENTS THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2022-09-29 WO disclosed
US-11344635-B2 Compounds for use as iron (III) MRI contrast agents containing anionic pendents and ancillary groups THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2022-05-31 US disclosed
WO-2020102820-A1 COMPOUNDS FOR USE AS IRON (III) MRI CONTRAST AGENTS CONTAINING ANIONIC PENDENTS AND ANCILLARY GROUPS THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2020-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11344635-B2 Compounds for use as iron (III) MRI contrast agents containing anionic pendents and ancillary groups SLC40A1, TAC3, ABCB7 HDAC1 785/4885HDAC4 1404/4885KCNH2 1528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.